Summary
Overactivity of the renin-angiotensin-aldosterone system occurs in the syndrome of congestive cardiac failure. Aldosterone overactivity is crucially involved in maintaining the oedematous state as evidenced by its often complete correction by adrenalectomy, or by aldosterone antagonists, in both experimental and clinical heart failure.
The hyperaldosteronism of heart failure can also be attacked by angiotensin-converting enzyme (ACE) inhibition, which not only blocks the angiotensin drive to aldosterone, but also unloads the heart by blocking renin-angiotensin-mediated vasoconstriction. Accordingly, ACE inhibition alone, if continued in full dosage, can often reduce or obviate the need for daily thiazide diuretic therapy. This specific, two-pronged therapy with fewer side effects emerges as a primary strategy for the treatment of congestive heart failure.
To learn more about why and how the renin system becomes involved in heart failure, the renal functional abnormalities have been re-examined. The effects of sodium administration on central haemodynamics and on the activity of the renin system have also been studied. This research has led to a consideration of the role of atrial natriuretic hormone in this pathophysiological interplay.
The study recharacterised renal haemodynamic patterns and indicated that in congestive heart failure there is a disproportionate diversion of blood away from the kidneys because of afferent vasoconstriction. However, the glomerular filtration rate is maintained by concurrent efferent arteriolar constriction, expressed by a rising filtration fraction. As heart failure advances, the filtration fraction can no longer rise. At this point, the glomerular filtration rate becomes flow-dependent and falls commensurately with the declining cardiac output. These intrarenal patterns may be mediated in part by increased intrarenal renin activity resulting from heart failure and diuretic therapy.
A further study of the abnormal renin system activity operating in heart failure has shown it to be very sensitive to dietary salt intake. Thus, consuming modest amounts of salt (100 mEq/day) was sufficient to markedly suppress renin and aldosterone values. However, since peripheral resistance was not changed, another non-renin, sodium-related mechanism must take over to sustain increased arterial constriction. The fact that captopril challenge evoked no response before and a large response after sodium depletion supports this concept.
Preliminary data suggest that atrial natriuretic hormone may also be important in congestive heart failure by opposing renin system activity at 4 sites. More research to define often crucial endocrine and renal abnormalities of heart failure could provide even more specific therapies.
Similar content being viewed by others
References
Ames RP, Borkowski AJ, Sicinski AM, Laragh JH. Prolonged infusion of angiotensin II and norepinephrine and blood pressure, electrolyte balance, aldosterone and cortisol secretion in normal man and in cirrhosis with ascites. Journal of Clinical Investigation 44: 1171–1186, 1965
Atlas SA, Kleinert HD, Camargo MJ, Januszewicz A, Sealey JE, et al. Purification, sequencing and synthesis of natriuretic and vasoactive rat atrial peptide. Nature 309: 717–719, 1984
Borkowski AJ, Howards SS, Laragh JH. Angiotensin and electrolyte excretion in renovascular hypertension. American Journal of Physiology 208: 1087–1092, 1965
Brunner HR, Kirshman JD, Sealey JE, Laragh JH. Hypertension of renal origin: evidence for two different mechanisms, Science 174: 1344–1346, 1971
Brunner HR, Laragh JH, Baer L, Newton MA, Goodwin FT, et al. Essential hypertension: renin and aldosterone, heart attack and stroke. New England Journal of Medicine 286: 441–449, 1972
Brunner HR, Gavras H, Laragh JH. Angiotensin II blockade in man by Sar1-ala-8-angiotensin II for understanding and treatment of high blood pressure. Lancet 2: 1045–1048, 1973
Brunner HR, Sealey JE, Laragh JH. Renin as a risk factor in essential hypertension: more evidence. In Laragh (Ed.) Hypertension manual, pp. 71–86, Dun-Donnelley Publishing Corporation, New York, 1974
Bühler FR, Laragh JH, Baer L, Vaughan Jr ED, Brunner HR. Propranolol inhibition of renin secretion: a specific approach to diagnosis and treatment of renin-dependent hypertensive disease. New England Journal of Medicine 287P: 1209–1214, 1972
Cannon PJ. The kidney in heart failure. New England Journal of Medicine 2906: 26–32, 1977
Case BD, Wallace JM, Keim HJ, Weber MA, Sealey JE, Laragh JH. Possible role of renin in hypertension as suggested by renin-sodium profiling and inhibition of converting enzyme. New England Journal of Medicine 296: 641–646, 1977
Cody RJ, Laragh JH. The role of the renin-angiotensin-aldosterone system in the pathophysiology of chronic heart failure. In Cohn (Ed.) Drug treatment of heart failure, pp. 35–51, Yorke Medical Books, New York, 1983
Cody RJ, Covit AB, Schaer GL, Laragh JH. Evaluation of a long-acting converting enzyme inhibitor (enalapril) for the treatment of chronic congestive heart failure. Journal of the American College of Cardiology 1: 1154–1159, 1983a
Cody RJ, Laragh JH, Case DB, Atlas SA. Renin system activity as a determinant of response to treatment in hypertension and heart failure. Hypertension 5(Suppl. 3): 36–42, 1983b
Cody RJ, Laragh JH, Atlas SA, Case DB. Converting enzyme inhibitor to identify and treat renin-mediated or sodium-volume related forms of increased peripheral resistance in hypertension and in congestive heart failure. Journal of Hypertension 1(Suppl. 1): 77–84, 1983c
Cody RJ, Covit AB, Schaer GL, Laragh JH, Sealey JE, Feldschuh J. Sodium and water balance in chronic congestive heart failure. Journal of Clinical Investigation 77: 1441–1452, 1986
Covit AB, Kubo SH, Feldschuh J, Laragh JH, Cody RJ. Factors influencing glomerular filtration rate (GFR) in patients with congestive heart failure (CHF). Journal of the American College of Cardiology 5: 529, 1985
Davis JO. Mechanisms of salt and water retention in congestive heart failure: the role of aldosterone. American Journal of Medicine 29: 486–491, 1960
de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Science 28: 89–94, 1981
de Bold AJ. Atrial natriuretic factor: a hormone produced by the heart. Science 230: 767, 1985
de Wardener HE, Mills IH, Clapham WF, Hayler CJ. Studies on the efferent mechanism of the sodium diuresis which follows the administration of intravenous saline in the dog. Clinical Science 21: 249–258, 1961
Dzau VJ, Colucci WS, Williams GH, Curfman G, Meggs L, et al. Sustained effectiveness of converting enzyme inhibition in patients with severe congestive heart failure. New England Journal of Medicine 302: 1373–1379, 1980
Gavras H, Brunner HR, Laragh JH, Sealey JE, Gavras I, Vukovitch RA. An angiotensin converting enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients. New England Journal of Medicine 291: 817–821, 1974
Gavras H, Brunner HR, Vaughan Jr ED, Laragh JH. Angiotensin-sodium interaction in blood pressure maintenance of renin hypertensive and normotensive rats. Science 180: 1369–1371, 1973
Goldsmith SR, Francis CS, Cowley AW, Levine TB, Cohn JN. Increased plasma arginine vasopressin levels in patients with congestive heart failure. Journal of the American College of Cardiology 1: 1385–1390, 1983
Ichikawa I, Pfeffer JM, Pfeffer MA, Hostetter TH, Brenner BM. Role of angiotensin II in the altered renal function of congestive heart failure. Circulation Research 55: 669–675, 1984
Kleinen HD, Maack T, Atlas SA, Januszewicz A, Sealey JE, Laragh JH. Atrial natriuretic factor inhibits angiotensin-, norepinephrine-, and potassium-induced vascular contractility. Hypertension 6(Suppl. 1): 143–147, 1984
Kluger J, Cody RJ, Laragh JH. The contributions of sympathetic tone and the renin-angiotensin system to severe chronic congestive heart failure: response to specific inhibitors. American Journal of Cardiology 49: 1667–1674, 1982
Laragh JH. Hormones in the pathogenesis of congestive heart failure: vasopressin, aldosterone and angiotensin II. Circulation 25: 1015–1023, 1962
Laragh JH. The renin-angiotensin-aldosterone system for blood pressure regulation and for subdividing patients to reveal and analyse different forms of hypertension. In Laragh, Bühler, Seldin (Eds). Frontiers in hypertension research, pp. 236–239, Springer-Verlag, New York, 1981
Laragh JH (Chairman). Calcium metabolism and calcium channel blockers for understanding and treating hypertension. American Journal of Medicine (Suppl. 6B) 77: 1–23, 1984a
Laragh JH. The meaning of plasma renin measurements: renin and sodium volume-mediated (low renin) forms of vasoconstriction in experimental and human hypertension and in the oedematous states of nephrosis and heart failure. Journal of Hypertension 2(Suppl. 1): 141–150, 1984b
Laragh JH. Atrial natriuretic hormone, the renin axis, and blood pressure-electrolyte homeostasis. New England Journal of Medicine 313: 1330–1430, 1985
Laragh JH, Cannon PJ. Endocrine factors in congestive heart failure: vasopressin, aldosterone and angiotensin. Medical Clinics of North America 46: 1471–1495, 1962
Laragh JH, Gilman A. Mechanisms of edema formation and principles of management. Combined Staff Clinic. American Journal of Medicine 21: 423–441, 1956
Laragh JH, VanDyke HB, Jacobson J, Adamson Jr K, Engle SL. The experimental production of ascites in the dog with diabetes insipidus. Journal of Clinical Investigation 35: 897–903, 1956
Laragh JH, Cannon PJ, Bentzel CJ, Sicinski AM, Meltzer JI. Angiotensin II, norepinephrine and the renal transport of electrolytes and water in normal man and in cirrhosis with ascites. Journal of Clinical Investigation 42: 1179–1192, 1963
Laragh JH, Sealey JE, Bühler FR, Vaughan Jr ED, Brunner HR, et al. The renin axis and vasoconstriction volume analysis for understanding and treating renovascular and renal hypertension. American Journal of Medicine 58: 4–13, 1975
Levine TB, Francis GS, Goldsmith SR, Simon AB, Cohn JN. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. American Journal of Cardiology 49: 1659–1666, 1982
Maack T, Camargo MJF. Atrial natriuretic factor: structure and functional properties. Kidney International 27: 607–615, 1985
Maack T, Marion DN, Camargo MJF, Kleinert JD, Laragh JH, et al. Effects of auriculin (atrial natriuretic factor) on blood pressure, renal function, and the renin-aldosterone system in dogs. American Journal of Medicine 77: 1069–1075, 1984
Müller FB, Bolli P, Erne P, Kiowski W, Bühler FR. Use of calcium channel blockers as monotherapy in the management of hypertension. American Journal of Medicine 77(Suppl. 2B): 11–15, 1984
Tarazi RC, Fouad FM, Ceimo JK, Bravo EL. Renin, aldosterone, and cardiac decompensation: studies with an oral converting enzyme inhibitor in heart failure. American Journal of Cardiology 44: 1013–1018, 1979
Thomas JA, Marks BH. Plasma norepinephrine in congestive heart failure. American Journal of Cardiology 41: 223–243, 1978
Sealey JE, Kirshman JE, Laragh JH. Natriuretic activity in plasma and urine of salt-loaded man and sheep. Journal of Clinical Investigation 48: 2210–2224, 1969
Vaughan Jr ED, Laragh JH, Gavras I, Bühler FR, Gavras H, et al. Volume factor in low and normal renin essential hypertension: treatment with either spironolactone or chlorthalidone. American Journal of Cardiology 32: 523–532, 1973
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Laragh, J.H. Endocrine Mechanisms in Congestive Cardiac Failure. Drugs 32 (Suppl 5), 1–12 (1986). https://doi.org/10.2165/00003495-198600325-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-198600325-00002